<DOC>
	<DOCNO>NCT00594230</DOCNO>
	<brief_summary>This single arm Phase II study .</brief_summary>
	<brief_title>LBH589 Refractory Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description>LBH589 ( 20 mg PO ) administer three time week Monday , Wednesday Friday . Treatment give 21 day follow 7 day rest period repeat every 28 day . Patients assessed toxicity ongoing basis disease assessment determine every 2 treatment cycle ( 8 week ) . Patients allow continue treatment maximum eight four week treatment cycle . Treatment discontinue evidence disease progression , unacceptable toxicity and/or discretion investigator .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Histologically cytological document diagnosis myelodysplastic syndrome ( MDS ) . Male female patient age &gt; = 18 year old . MDS patient fail hypomethylating ( azacitidine decitabine ) therapy . Patients 5qcytogenic abnormality must also progress intolerant lenalidomide . Patients include 30 % blast ( FAB RAEBT ) eligible enroll . CMML &gt; = 5 % blast eligible enroll . ECOG PS 0 , 1 2 . Laboratory value must follow : Bilirubin &lt; = 1.5 mg/dL AST/SGOT &lt; = 2.5 x ULN ALT/SGPT Creatinine &lt; = 2.0 mg/dL 24hour Creatinine Clearance &gt; = 50 ml/min Albumin &gt; = 3 g/dL Potassium &gt; = low limit normal ( LLN ) Phosphorous &gt; = LLN Calcium &gt; = LLN Magnesium &gt; = LLN Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Life expectancy &gt; = 12 week . Prior treatment HDAC inhibitor . Prior intensive chemotherapy high dose araC ( &gt; = 1 gm/m2 ) More one prior single agent chemotherapy regimen . Prior hydroxyurea cytoreduction permit however . Impaired cardiac function Active CNS disease , include leptomeningeal metastasis . Unresolved diarrhea &gt; CTCAE grade 1 . Chemotherapy , investigational drug therapy , major surgery &lt; 4 week prior start study drug patient recover side effect previous therapy . Patient &lt; 5 year free another primary malignancy except primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . Women pregnant breast feed woman childbearing potential ( WOCBP ) willing use double barrier method contraception study 3 month end treatment . One method contraception must barrier method . Male patient whose sexual partner WOCBP use double method contraception study 3 month end treatment . One method must condom . Patients gastrointestinal ( GI ) tract disease , cause inability take oral medication , malabsorption syndrome , requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) . Other concurrent severe , uncontrolled systemic fungal , bacterial , viral infection intercurrent illness , include limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Patients uncontrolled coagulopathy . Abnormal thyroid function ( TSH free T4 ) detect screen . Patients known hypothyroidism stable thyroid replacement eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Myelodysplastic Syndromes ( MDS )</keyword>
	<keyword>Refractory</keyword>
	<keyword>LBH589</keyword>
</DOC>